The company intends to focus on the marketing and development of its Biocoral® and related products. The company anticipates realizing and increasing its revenues from the sale of Biocoral® in particular by starting the marketing its products in the treatment of bone disease associated to bone demineralisation and or low bone masse (osteoporotic fractures and theirs prevention). The company had conducted a multicenter clinical trail in this application and hold the different international issued patents protecting the use of its products and other similar product (including the product composed on calcium phosphate "Hydroxyapatite") in this application .

In addition the company has also obtainded all authorizations necessary for the sale of Biocoral® in Canada, and has identified the requirements for this application and approached a US medical supply distributor in order to access the US market. An accredited scientific team in the US has conducted human clinical studies with a 5 year follow up to confirm bone reconstruction in oral application which confirmed the stability of the successful result and management believes that this study will facilitate FDA approval for our product used in this indication when we file for FDA approval.